Alnylam Pharmaceuticals, Inc. (ALNY) fair value analysis
Nasdaq · Updated 2026-09-07
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes medicines based on RNA interference technology to treat rare genetic diseases and other conditions. The company operates globally with operations across the United States, Europe, and other international markets.
Valuation status
Awaiting full valuationALNY does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $220.33
- Sector
- Healthcare
- 12-month range
- $220.33–$460.65
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- C-
- Leverage
- High
- RSI zone
- Neutral
- 50/200-day trend
- Downtrend
- 52-week position
- The bottom quarter of its range
What our data shows for ALNY
- Our model validated 2 trailing price-to-earnings windows for ALNY, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $220.33–$460.65.
- The 14-day relative strength index sits at a neutral 69.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ALNY
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent ALNY news
TickrTrends' derived news-sentiment signal for ALNY is currently leaning positive, computed from recent coverage.
- Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript (seekingalpha.com, 2026-09-08)
TickrTrends take: Alnylam Pharmaceuticals presented at the Wells Fargo healthcare conference, an event where companies typically discuss pipeline progress and commercial strategy with investors. For valuation-focused readers, the key takeaway from such presentations is usually management commentary on revenue drivers, R&D efficiency, and competitive positioning in the RNA interference therapeutics space. Given that TickrTrends is currently awaiting full valuation data on ALNY, investors should monitor whether the company provided concrete guidance or updates on product adoption and manufacturing scale that could inform future earnings estimates. - Madrigal Pharmaceuticals (MDGL) Leads Healthcare CapEx Growth Amid Elevated Price-to-Sales Valuation (gurufocus.com, 2026-09-02)
TickrTrends take: Alnylam Pharmaceuticals operates in the same Healthcare sector as Madrigal Pharmaceuticals, where capital expenditure growth patterns can signal shifting competitive dynamics and investor appetite for the industry. TickrTrends is currently awaiting full valuation data for ALNY, meaning investors watching this stock should monitor whether healthcare companies' elevated price-to-sales multiples persist or normalize as the sector's capital spending cycle evolves. Understanding where ALNY sits relative to peers experiencing significant CapEx growth will be important context once its full valuation profile becomes available. - ALNY Looks 55.6% Undervalued on GF Value™ Amid New Cardiovascular RNAi Data (gurufocus.com, 2026-08-30)
TickrTrends take: Alnylam Pharmaceuticals trades with significant undervaluation according to GF Value analysis, suggesting the market may not fully reflect the company's potential in cardiovascular applications through its RNAi technology platform. TickrTrends currently awaits a complete valuation assessment for the Healthcare sector company, meaning investors focused on valuation metrics should monitor how new cardiovascular data influences the company's earnings trajectory and competitive positioning. The gap between current market pricing and fundamental value estimates could shift materially as clinical and commercial progress in this therapeutic area becomes clearer to the market.
What people are saying
Follow the ALNY conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ALNY stock undervalued?
ALNY does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is ALNY's TickrTrends verdict?
ALNY is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is ALNY overbought or oversold?
ALNY's 14-day RSI is in neutral territory - neither overbought nor oversold.